美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Sanofi

98.70

+2.032.10%

成交量：270.00

成交額：2.66萬

市值：1,237.35億

市盈率：18.10

高：98.70

開：98.70

低：98.70

收：96.68

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

賽諾菲將於第三季度開始全球運送Beyfortus RSV預防治療藥物Sanofi to Begin Global Shipments of Beyfortus RSV Prevention Treatment in Third Quarter

賽諾菲和再生元公司報告了針對IL-33通路的COPD藥物的混合三期試驗結果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway

Viz.ai與賽諾菲和再生元合作，利用人工智能技術改善COPD護理Viz.ai Partners with Sanofi and Regeneron to Improve COPD Care with AI Technology

SP0273 & SP0237——Sanofi流感疫苗管線

生物制品圈

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SNYNF"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNYNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNYNF\",,,,,undefined,":{"symbol":"SNYNF","market":"US","secType":"STK","nameCN":"Sanofi","latestPrice":98.704,"timestamp":1752264000000,"preClose":96.675,"halted":0,"volume":270,"delay":15,"floatShares":1102808708,"shares":1253592721,"eps":5.452053,"marketStatus":"休市中","change":2.029,"latestTime":"07-11 16:00:00 EDT 延時","open":98.704,"high":98.704,"low":98.704,"amount":26596.909999999993,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":5.452053,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":96.675,"volumeRatio":0.003339228514950991},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNYNF\",,,,,undefined,":{"symbol":"SNYNF","floatShares":1102808708,"roa":"4.28%","roe":"7.30%","lyrEps":4.599879,"volumeRatio":0.003339228514950991,"shares":1253592721,"dividePrice":4.368662,"high":98.704,"amplitude":0,"preClose":96.675,"low":98.704,"week52Low":91.81,"pbRate":"1.37","psRate":"2.34","week52High":122.028,"institutionHeld":0,"latestPrice":98.704,"eps":5.452053,"divideRate":0.04426,"volume":270,"delay":15,"ttmEps":5.452053,"open":98.704,"prevYearClose":95.1001,"prevWeekClose":98.332,"prevMonthClose":94.9899,"prevQuarterClose":94.9899,"fiveDayClose":98.332,"twentyDayClose":98.416,"sixtyDayClose":101.486},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SNYNF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNYNF\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545100384","title":"賽諾菲將於第三季度開始全球運送Beyfortus RSV預防治療藥物Sanofi to Begin Global Shipments of Beyfortus RSV Prevention Treatment in Third Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2545100384","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545100384?lang=zh_tw&edition=fundamental","pubTime":"2025-06-21 14:06","pubTimestamp":1750485960,"startTime":"0","endTime":"0","summary":"The decision comes as part of Sanofi’s strategy to ensure timely availability of Beyfortus, particularly during a period when demand for RSV prevention typically increases. By initiating shipments in Q3, the company aims to support healthcare systems worldwide in preparing for the seasonal rise in RSV cases.该决定是赛诺菲确保 Beyfortus 及时供应战略的一部分，尤其是在对 RSV 预防需求通常增加的时期。通过在第三季度开始发货，该公司旨在支持全球医疗系统为 RSV 病例的季节性增长做好准备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621140922952592c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621140922952592c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GCVRZ","SNYNF","SNY","BK4585","IE00BFXG1179.USD","BK4588"],"gpt_icon":0},{"id":"2539221846","title":"賽諾菲和再生元公司報告了針對IL-33通路的COPD藥物的混合三期試驗結果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221846","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539221846?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 19:09","pubTimestamp":1748603340,"startTime":"0","endTime":"0","summary":"Following the announcement, both companies experienced a decline in their stock prices..公告发布后，两家公司的股价均出现下跌。The studies assessed itepekimab’s efficacy in reducing exacerbations among COPD patients who were former smokers. While the drug showed potential in lowering flare-ups compared to standard treatments, it did not achieve statistically significant improvements across all primary endpoints. The trials aimed to explore whether targeting interleukin-33 , an inflammatory pathway linked to COPD progression, could offer new therapeutic benefits.这些研究评估了伊替普单抗在减少曾吸烟的慢性阻塞性肺病患者急性加重方面的疗效。试验旨在探索针对白细胞介素-33这一与COPD进展相关的炎症通路，是否能提供新的治疗益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0114720955.EUR","LU0882574055.USD","LU0058720904.USD","LU0053666078.USD","REGN","LU2362541273.HKD","LU0109394709.USD","GCVRZ","BK4007","LU2089984988.USD","LU0289739699.SGD","LU0823434583.USD","BK4588","BK4139","BK4585","SNY","LU2106854487.HKD","LU2362540622.SGD","LU0823416689.USD","LU1917777945.USD","LU2362541513.USD","SNYNF","LU1974910355.USD","LU2468319806.SGD","LU0320765992.SGD","LU2023250504.SGD","LU2237438978.USD","LU0823434740.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2537092982","title":"Viz.ai與賽諾菲和再生元合作，利用人工智能技術改善COPD護理Viz.ai Partners with Sanofi and Regeneron to Improve COPD Care with AI Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2537092982","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537092982?lang=zh_tw&edition=fundamental","pubTime":"2025-05-21 19:14","pubTimestamp":1747826040,"startTime":"0","endTime":"0","summary":"Viz.ai has announced a multi-year collaboration with global healthcare company Sanofi and biotechnology firm Regeneron to support the management of chronic obstructive pulmonary disease  using artificial intelligence .Viz.ai 宣布与全球医疗保健公司赛诺菲和生物技术公司再生元达成多年合作，利用人工智能  支持慢性阻塞性肺疾病  的管理。Through this partnership, Viz.ai, Sanofi, and Regeneron aim to address gaps in COPD care by advancing the use of AI to support earlier intervention and improve outcomes for patients living with this serious respiratory disease.通过这一合作，Viz.ai、赛诺菲和再生元旨在通过推进人工智能的使用来弥补COPD护理中的不足，支持更早的干预，并改善患有这种严重呼吸系统疾病患者的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505211915209760b85e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505211915209760b85e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823434740.USD","LU0882574055.USD","LU0109394709.USD","BK4585","LU2362541273.HKD","LU0320765992.SGD","BK4007","LU0053666078.USD","LU0889565916.HKD","SNYNF","SNY","LU0823434583.USD","LU0058720904.USD","LU2106854487.HKD","LU2089984988.USD","LU2362541513.USD","LU2362540622.SGD","LU0823416689.USD","LU1974910355.USD","BK4139","LU0114720955.EUR","LU2237438978.USD","LU1917777945.USD","GCVRZ","LU2023250504.SGD","LU0289739699.SGD","REGN","BK4588","LU2468319806.SGD"],"gpt_icon":0},{"id":"2535692001","title":"SP0273 & SP0237——Sanofi流感疫苗管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2535692001","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535692001?lang=zh_tw&edition=fundamental","pubTime":"2025-05-14 23:02","pubTimestamp":1747234975,"startTime":"0","endTime":"0","summary":"2024年7月25日，Sanofi发布的第二季度财报中，流感疫苗作为公司的优势品种，二季度销售额达到了1.15亿欧元。在2023年6月举办的Sanofi投资者活动上，公司公布了SP0273疫苗的最新试验结果。图2SP0273的临床试验结果此外，在同一活动上，Sanofi还透露了一项令人振奋的研发进展，公司正借助机器学习的力量，致力于新一代流感mRNA疫苗的研发。不过，这一变动并未减缓Sanofi在流感mRNA疫苗研发领域的步伐。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515025403a47e821c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515025403a47e821c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GCVRZ","IE00BFXG1179.USD","SNY","BK4007","SNYNF","BK4585","BK4588"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNYNF\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"SNYNF","amount":3.92,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-13","defaultRemindTime":1747056600000,"name":"Sanofi","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-05-13","currency":"EUR","dateTimestamp":1747022400000,"payDate":"2025-05-14"},{"date":"2024-05-13","symbol":"SNYNF","amount":3.76,"announcedDate":"2024-02-01","type":"dividend","market":"US","newRecordDate":"2024-05-14","defaultRemindTime":1715607000000,"name":"Sanofi","recordDate":"2024-05-15","payableDate":"2024-05-14","currency":"EUR","dateTimestamp":1715572800000,"payDate":"2024-05-15"},{"market":"US","date":"2024-04-25","symbol":"SNYNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"pre","actualEps":null},{"date":"2023-05-30","symbol":"SNYNF","amount":3.56,"announcedDate":"2023-02-03","type":"dividend","market":"US","newRecordDate":"2023-05-31","defaultRemindTime":1685453400000,"name":"Sanofi","recordDate":"2023-06-01","payableDate":"2023-05-31","currency":"EUR","dateTimestamp":1685419200000,"payDate":"2023-06-01"},{"date":"2022-10-28","symbol":"SNYNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666944000000,"name":null,"time":"盤前","dateTimestamp":1666929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNYNF\",market:\"US\",,,undefined,":[{"executeDate":"2019-05-09","recordDate":"2019-05-10","paymentDate":"2019-05-13","value":3.07,"currency":"EUR"},{"executeDate":"2020-05-04","recordDate":"2020-05-05","paymentDate":"2020-05-06","value":3.15,"currency":"EUR"},{"executeDate":"2021-05-05","recordDate":"2021-05-06","paymentDate":"2021-05-07","value":3.2,"currency":"EUR"},{"executeDate":"2022-05-06","recordDate":"2022-05-09","paymentDate":"2022-05-10","value":3.33,"currency":"EUR"},{"executeDate":"2023-05-30","recordDate":"2023-05-31","paymentDate":"2023-06-01","value":3.56,"currency":"EUR"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNYNF\",market:\"US\",delay:false,,,undefined,":{}}}